Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/4H2HFFUFYBBYDD5FU42WJNVWJ4.jpg)
Shares of world’s most valuable pharmaceuticals group reapproach record highs
A look at North American equities heading in both directions
Doctors and pharmacies have reported huge demand for Mounjaro and Zepbound in recent months, causing widespread shortages of the popular drugs.